Altered fractionation short-course radiotherapy for stage II-III rectal cancer: a retrospective study.

Purpose: To report the long-term outcomes of neoadjuvant altered fractionation short-course radiotherapy in 271 consecutive patients with stage II-III rectal cancer.

Patients And Methods: This was a retrospective single institution study with median follow-up of 101 months (8.4 years).

Risk Factors for Local Relapse and Inferior Disease-free Survival After Breast-conserving Management of Breast Cancer: Recursive Partitioning Analysis of 2161 Patients.

Background: The purpose of this study was to analyze risk factors for ipsilateral in-breast relapse and inferior disease-free survival (DFS) after standard adjuvant whole-breast radiotherapy (± boost and systemic treatment) as part of a multimodal breast-conserving approach.

Patients And Methods: Decision trees were built through recursive partitioning analysis (RPA). The median follow-up for all 2161 patients was 114 months (9.

ÖGRO survey on radiotherapy capacity in Austria : Status quo and estimation of future demands.

Background: A comprehensive evaluation of the current national and regional radiotherapy capacity in Austria with an estimation of demands for 2020 and 2030 was performed by the Austrian Society for Radiation Oncology, Radiobiology and Medical Radiophysics (ÖGRO).

Materials And Methods: All Austrian centers provided data on the number of megavoltage (MV) units, treatment series, fractions, percentage of retreatments and complex treatment techniques as well as the daily operating hours for the year 2014. In addition, waiting times until the beginning of radiotherapy were prospectively recorded over the first quarter of 2015.

Divorcing the puzzles: When group identities foster in-group cooperation.

We argue that general social psychological mechanisms (e.g., common group identity) can account for prosocial behavior and cooperative norms without the need for punishing Big Gods.

[Reirradiation of recurrent glioblastoma].

Patients with glioblastoma are treated by radiotherapy in combination with temozolamid. Recurrent and progressive disease can be managed by several treatment options. Some series reported about reirradiation of brain tumors, but there are no randomised studies.